Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q92620

UPID:
PRP16_HUMAN

ALTERNATIVE NAMES:
ATP-dependent RNA helicase DHX38; DEAH box protein 38

ALTERNATIVE UPACC:
Q92620; B4DVG8; D3DWS7; O75212; Q96HN7

BACKGROUND:
The protein Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16, known alternatively as ATP-dependent RNA helicase DHX38 and DEAH box protein 38, is integral to the mRNA splicing process. Its function as an ATP-binding RNA helicase within the spliceosome complex is critical for the accurate excision of introns, ensuring the correct assembly of mRNA.

THERAPEUTIC SIGNIFICANCE:
Given its pivotal role in mRNA splicing and its link to Retinitis pigmentosa 84, a debilitating visual impairment, Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 presents a promising target for therapeutic research. Exploring this protein's function could unveil new pathways for treating or managing this progressive retinal disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.